This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.
Top Research Reports for NVIDIA, Netflix & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Netflix, and Goldman Sachs, as well as a micro-cap stock, AMREP.
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
by Kinjel Shah
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
by Kinjel Shah
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
Insights Into Astrazeneca (AZN) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
by Zacks Equity Research
Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
by Zacks Equity Research
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
by Kinjel Shah
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
by Kinjel Shah
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?
by Urmimala Biswas
TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
by Kinjel Shah
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
The Zacks Analyst Blog Highlights T-Mobile US, AstraZeneca and Comcast
by Zacks Equity Research
TMUS, AZN, and CMCSA show diverging paths as 5G gains, pipeline growth, and streaming resilience shape their outlooks.
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast
by Mark Vickery
TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
by Kinjel Shah
AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
by Zacks Equity Research
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.